search
Back to results

SMART Clinical Study: Surgical Multi-center Assessment of RF Ablation for the Treatment of Vertebrogenic Back Pain (SMART)

Primary Purpose

Low Back Pain

Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Intracept Treatment
Sham Treatment
Sponsored by
Relievant Medsystems, Inc.
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Low Back Pain focused on measuring chronic axial low back pain, vertebrogenic pain, Radio frequency ablation

Eligibility Criteria

25 Years - 70 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Skeletally mature patients age 25 - 70 years, inclusive
  • Chronic lower back pain for at least six (6) months
  • Failure to respond to at least six (6) months of non-operative conservative management. The minimum requirement is as follows:

    • Analgesic therapy (minimum of 2 weeks) and a minimum of 4 weeks of NSAID therapy
    • Supervised exercise program(minimum of 12 sessions)
  • Oswestry Disability Index (ODI) at time of evaluation of at least 30 points
  • Baseline Visual Analog Scale (VAS) of at least 4cm on a 10cm scale
  • The following test indicating that the vertebral body is the source of pain:

    1.MRI showing Type 1 or Type II Modic changes at least one vertebral endplate, at one or more levels from L3 to S1

  • Understands the local language and is willing and able to follow the requirements of the protocol
  • Understands the informed consent and signs the institutional review board/ independent ethics committee (IRB/IEC) approved informed consent form

Exclusion Criteria:

  • Radicular pain by history or evidence of pain or neurological deficit in a dermatomal zone at or below the medial thigh.
  • Previous surgery performed on the lumbar spine
  • History of symptomatic spinal stenosis
  • History of osteoporotic or tumor-related vertebral body compression fracture
  • History of vertebral cancer or spinal metastasis
  • History of spinal infection
  • Metabolic bone disease (e.g. osteogenesis imperfecta)
  • BMI ≥40
  • Osteoporosis, defined as T score <-2.5
  • Any radiographic evidence of other important back pathology, such as:

    1. Nerve root compression or severe effacement of the thecal sac that correlates with radicular pain or muscle weakness
    2. Disc extrusion or disc protrusion >5mm
    3. Facet arthrosis or facet effusion at any lumbar level that correlates with clinical evidence of facet mediated low back pain
    4. Spondylolisthesis 2mm or greater at any level
    5. Spondylolysis at any level
  • MRI evidence of Modic changes, Type I or Type II at greater than 3 vertebral bodies.
  • Any back pathology related to trauma, evidence of vertebral compression fracture or other spinal pathology that could affect assessment of response to back pain
  • Demonstrates 3 or more Waddell's signs of Inorganic Behavior
  • Any evidence of current systemic infection
  • Uncorrected bleeding diathesis
  • Any neurologic problem that prevents early mobilization after surgery or interferes with assessment of ODI
  • Contraindication to MRI or patients who have allergies to the components of the Intracept device
  • Pregnant, lactating or plan to become pregnant in next year
  • Diabetes requiring daily insulin
  • Current use of steroid therapy, with the exception of inhalation steroids for asthma
  • Evidence of mental instability or uncontrolled depression; patients requiring anti-depressants or anti-psychotics within 3 months of enrollment are not eligible; patients with a Beck Depression Score of greater than 24 are not eligible
  • Receiving Workmen's Compensation
  • Currently involved in litigation regarding back pain/injury or financial incentive to remain impaired
  • Any medical condition that impairs follow-up
  • Contraindications to the proposed anesthetic protocol.
  • Evidence of substance abuse; patients using prescribed extended release narcotics are not eligible (e.g. fentanyl patch,MS contin, oxycontin)
  • Known to require at the time of screening and/or randomization, additional surgery to the lumbar spinal region within six months
  • Being treated with radiation, chemotherapy, immunosuppression, or chronic steroid therapy (prednisone use up to 5 mg/qd or its equivalent is allowed)
  • Has a life expectancy of less than 1 year
  • Has active implantable devices, such as cardiac pacemakers, spinal cord stimulators, etc.
  • Is a prisoner

Sites / Locations

  • Desert Institute for Spine Care
  • SpineCare Medical Group
  • Memorial Orthopedic Surgical Group
  • The Spine Institute
  • Pain Center Solutions
  • Indiana Spine Group
  • Maine Medical Partners
  • Partners in Research and Educational Studies of Spinal Disorders (PressD)
  • OrthoCarolina
  • NeuroSpine Institute
  • Rothman Institute
  • Seton Spine & Scoliosis Center
  • Virginia iSpine Physicians

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Sham Comparator

Arm Label

Intracept Treatment

Sham Treatment

Arm Description

Outcomes

Primary Outcome Measures

Change in ODI From Baseline to 3 Months Post-treatment
The primary variable is the Oswestry Disability Index (ODI) and the primary efficacy endpoint is the mean improvement from baseline to 3 months in the ODI. The primary endpoint will be evaluated in both the treatment and sham groups with between-group comparisons used to assess the success of the Intracept System in reducing chronic axial low back pain. ODI is a patient questionnaire that assesses back dysfunction due to back pain. There are 10 questions that are scored from 0-5. The obtained score is multiplied by 2 to produce a percentage score that is reported on a scale of 0-100. Scores are interpreted as follows: 0-20% minimum disability; 21-40% moderate disability; 41-60% severe disability; 61-80% crippled; 81-100% bed bound or exaggerating their symptoms.

Secondary Outcome Measures

Patient Success at 3 Months
Proportion of subjects with clinical success at 3 months, where clinical success was defined as: 3 month ODI score represented at least a 15-point reduction from baseline no device or procedure related SAE between baseline and 3 mos. no increase in opioid use between procedure and 3 mos. no deficit in a motor or dermatomal sensory group at the treated level at 3 mos. no operative interventions or invasive procedures for lumbar back pain by a pain management or spinal specialist between procedure and 3 mos.
Change in ODI From Baseline to 6 Months Post-treatment
The improvement in ODI at 6 months compared to baseline. ODI is a patient questionnaire that assesses back dysfunction due to back pain. There are 10 questions that are scored from 0-5. The obtained score is multiplied by 2 to produce a percentage score that is reported on a scale of 0-100. Scores are interpreted as follows: 0-20% minimum disability; 21-40% moderate disability; 41-60% severe disability; 61-80% crippled; 81-100% bed bound or exaggerating their symptoms.

Full Information

First Posted
October 3, 2011
Last Updated
October 24, 2016
Sponsor
Relievant Medsystems, Inc.
search

1. Study Identification

Unique Protocol Identification Number
NCT01446419
Brief Title
SMART Clinical Study: Surgical Multi-center Assessment of RF Ablation for the Treatment of Vertebrogenic Back Pain
Acronym
SMART
Official Title
A Prospective Randomized, Double-blind, Controlled Investigation Evaluating the Intracept Intraosseous Nerve Ablation System for the Reduction of Pain in Patients With Chronic Axial Low Back Pain
Study Type
Interventional

2. Study Status

Record Verification Date
October 2016
Overall Recruitment Status
Completed
Study Start Date
October 2011 (undefined)
Primary Completion Date
March 2015 (Actual)
Study Completion Date
March 2016 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Relievant Medsystems, Inc.

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
To evaluate the safety and efficacy of RF ablation using the Intracept Intraosseous Nerve Ablation System to ablate intraosseous nerves for the relief of chronic axial low back pain. This is a prospective, double-blind, randomized, sham-controlled clinical trial with an optional crossover component.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Low Back Pain
Keywords
chronic axial low back pain, vertebrogenic pain, Radio frequency ablation

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Crossover Assignment
Masking
ParticipantOutcomes Assessor
Allocation
Randomized
Enrollment
225 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Intracept Treatment
Arm Type
Experimental
Arm Title
Sham Treatment
Arm Type
Sham Comparator
Intervention Type
Device
Intervention Name(s)
Intracept Treatment
Intervention Description
Percutaneous transpedicular RF ablation of an intraosseous nerve within the lumbar vertebral body to treat chronic axial low back.
Intervention Type
Device
Intervention Name(s)
Sham Treatment
Intervention Description
Percutaneous transpedicular access to the lumbar vertebra, no RF ablation delivered.
Primary Outcome Measure Information:
Title
Change in ODI From Baseline to 3 Months Post-treatment
Description
The primary variable is the Oswestry Disability Index (ODI) and the primary efficacy endpoint is the mean improvement from baseline to 3 months in the ODI. The primary endpoint will be evaluated in both the treatment and sham groups with between-group comparisons used to assess the success of the Intracept System in reducing chronic axial low back pain. ODI is a patient questionnaire that assesses back dysfunction due to back pain. There are 10 questions that are scored from 0-5. The obtained score is multiplied by 2 to produce a percentage score that is reported on a scale of 0-100. Scores are interpreted as follows: 0-20% minimum disability; 21-40% moderate disability; 41-60% severe disability; 61-80% crippled; 81-100% bed bound or exaggerating their symptoms.
Time Frame
3 months
Secondary Outcome Measure Information:
Title
Patient Success at 3 Months
Description
Proportion of subjects with clinical success at 3 months, where clinical success was defined as: 3 month ODI score represented at least a 15-point reduction from baseline no device or procedure related SAE between baseline and 3 mos. no increase in opioid use between procedure and 3 mos. no deficit in a motor or dermatomal sensory group at the treated level at 3 mos. no operative interventions or invasive procedures for lumbar back pain by a pain management or spinal specialist between procedure and 3 mos.
Time Frame
3 months
Title
Change in ODI From Baseline to 6 Months Post-treatment
Description
The improvement in ODI at 6 months compared to baseline. ODI is a patient questionnaire that assesses back dysfunction due to back pain. There are 10 questions that are scored from 0-5. The obtained score is multiplied by 2 to produce a percentage score that is reported on a scale of 0-100. Scores are interpreted as follows: 0-20% minimum disability; 21-40% moderate disability; 41-60% severe disability; 61-80% crippled; 81-100% bed bound or exaggerating their symptoms.
Time Frame
6 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
25 Years
Maximum Age & Unit of Time
70 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Skeletally mature patients age 25 - 70 years, inclusive Chronic lower back pain for at least six (6) months Failure to respond to at least six (6) months of non-operative conservative management. The minimum requirement is as follows: Analgesic therapy (minimum of 2 weeks) and a minimum of 4 weeks of NSAID therapy Supervised exercise program(minimum of 12 sessions) Oswestry Disability Index (ODI) at time of evaluation of at least 30 points Baseline Visual Analog Scale (VAS) of at least 4cm on a 10cm scale The following test indicating that the vertebral body is the source of pain: 1.MRI showing Type 1 or Type II Modic changes at least one vertebral endplate, at one or more levels from L3 to S1 Understands the local language and is willing and able to follow the requirements of the protocol Understands the informed consent and signs the institutional review board/ independent ethics committee (IRB/IEC) approved informed consent form Exclusion Criteria: Radicular pain by history or evidence of pain or neurological deficit in a dermatomal zone at or below the medial thigh. Previous surgery performed on the lumbar spine History of symptomatic spinal stenosis History of osteoporotic or tumor-related vertebral body compression fracture History of vertebral cancer or spinal metastasis History of spinal infection Metabolic bone disease (e.g. osteogenesis imperfecta) BMI ≥40 Osteoporosis, defined as T score <-2.5 Any radiographic evidence of other important back pathology, such as: Nerve root compression or severe effacement of the thecal sac that correlates with radicular pain or muscle weakness Disc extrusion or disc protrusion >5mm Facet arthrosis or facet effusion at any lumbar level that correlates with clinical evidence of facet mediated low back pain Spondylolisthesis 2mm or greater at any level Spondylolysis at any level MRI evidence of Modic changes, Type I or Type II at greater than 3 vertebral bodies. Any back pathology related to trauma, evidence of vertebral compression fracture or other spinal pathology that could affect assessment of response to back pain Demonstrates 3 or more Waddell's signs of Inorganic Behavior Any evidence of current systemic infection Uncorrected bleeding diathesis Any neurologic problem that prevents early mobilization after surgery or interferes with assessment of ODI Contraindication to MRI or patients who have allergies to the components of the Intracept device Pregnant, lactating or plan to become pregnant in next year Diabetes requiring daily insulin Current use of steroid therapy, with the exception of inhalation steroids for asthma Evidence of mental instability or uncontrolled depression; patients requiring anti-depressants or anti-psychotics within 3 months of enrollment are not eligible; patients with a Beck Depression Score of greater than 24 are not eligible Receiving Workmen's Compensation Currently involved in litigation regarding back pain/injury or financial incentive to remain impaired Any medical condition that impairs follow-up Contraindications to the proposed anesthetic protocol. Evidence of substance abuse; patients using prescribed extended release narcotics are not eligible (e.g. fentanyl patch,MS contin, oxycontin) Known to require at the time of screening and/or randomization, additional surgery to the lumbar spinal region within six months Being treated with radiation, chemotherapy, immunosuppression, or chronic steroid therapy (prednisone use up to 5 mg/qd or its equivalent is allowed) Has a life expectancy of less than 1 year Has active implantable devices, such as cardiac pacemakers, spinal cord stimulators, etc. Is a prisoner
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Jeffrey Fischgrund, MD
Organizational Affiliation
Michigan Orthopaedic Institute
Official's Role
Principal Investigator
Facility Information:
Facility Name
Desert Institute for Spine Care
City
Phoenix
State/Province
Arizona
ZIP/Postal Code
85020
Country
United States
Facility Name
SpineCare Medical Group
City
Daly City
State/Province
California
ZIP/Postal Code
94015
Country
United States
Facility Name
Memorial Orthopedic Surgical Group
City
Long Beach
State/Province
California
ZIP/Postal Code
90806
Country
United States
Facility Name
The Spine Institute
City
Santa Monica
State/Province
California
ZIP/Postal Code
90403
Country
United States
Facility Name
Pain Center Solutions
City
Marietta
State/Province
Georgia
ZIP/Postal Code
30060
Country
United States
Facility Name
Indiana Spine Group
City
Carmel
State/Province
Indiana
ZIP/Postal Code
46032
Country
United States
Facility Name
Maine Medical Partners
City
Scarborough
State/Province
Maine
ZIP/Postal Code
04074
Country
United States
Facility Name
Partners in Research and Educational Studies of Spinal Disorders (PressD)
City
Southfield
State/Province
Michigan
ZIP/Postal Code
48033
Country
United States
Facility Name
OrthoCarolina
City
Charlotte
State/Province
North Carolina
ZIP/Postal Code
28207
Country
United States
Facility Name
NeuroSpine Institute
City
Eugene
State/Province
Oregon
ZIP/Postal Code
97401
Country
United States
Facility Name
Rothman Institute
City
Philadelphia
State/Province
Pennsylvania
ZIP/Postal Code
19107
Country
United States
Facility Name
Seton Spine & Scoliosis Center
City
Austin
State/Province
Texas
ZIP/Postal Code
78731
Country
United States
Facility Name
Virginia iSpine Physicians
City
Richmond
State/Province
Virginia
ZIP/Postal Code
23235
Country
United States

12. IPD Sharing Statement

Learn more about this trial

SMART Clinical Study: Surgical Multi-center Assessment of RF Ablation for the Treatment of Vertebrogenic Back Pain

We'll reach out to this number within 24 hrs